Compare HMY & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | TECH |
|---|---|---|
| Founded | 1950 | 1976 |
| Country | South Africa | United States |
| Employees | 34350 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 10.2B |
| IPO Year | N/A | 1995 |
| Metric | HMY | TECH |
|---|---|---|
| Price | $16.87 | $53.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $16.00 | ★ $73.09 |
| AVG Volume (30 Days) | ★ 3.8M | 2.1M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 0.88% | 0.61% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | N/A | ★ $1,219,635,000.00 |
| Revenue This Year | $40.34 | $2.49 |
| Revenue Next Year | $22.08 | $6.40 |
| P/E Ratio | ★ $15.60 | $108.12 |
| Revenue Growth | N/A | ★ 5.23 |
| 52 Week Low | $11.85 | $46.02 |
| 52 Week High | $26.04 | $72.16 |
| Indicator | HMY | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 30.55 | 35.54 |
| Support Level | $15.75 | $48.52 |
| Resistance Level | $22.11 | $54.08 |
| Average True Range (ATR) | 0.85 | 2.25 |
| MACD | -0.41 | -0.31 |
| Stochastic Oscillator | 6.64 | 18.36 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.